<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="wordpress.com" -->
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd"
	xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
	xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
	xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"
	>
<url><loc>https://fdawatch.net/2026/07/27/fda-legal-regulatory-compliance-issues-part-2-customs-regulation-international-trade/</loc><news:news><news:publication><news:name>FDA Watch Podcast</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-07-27T13:39:25+00:00</news:publication_date><news:title>FDA Legal, Regulatory &#038; Compliance Issues, Part 2: Customs Regulation &#038; International Trade</news:title><news:keywords>FDA, regulation, pharmaceuticals, medical devices, drugs, compliance, biologics, politics, supply chain, tariffs, regulatory policy, China, AGG, legal, Allison Raley, Luis Arandia Jr., Arnall Golden Gregory, trade, import, export, Section 232, duty exposure, forced labor, global, trade policy, international trade, customs, economy, trump</news:keywords></news:news><image:image><image:loc>https://fdawatch.net/wp-content/uploads/2025/08/fdawatch_artworkupdated8.5.jpg?w=150</image:loc></image:image></url></urlset>
